Developing CIPN and HSR Models Using Paclitaxel and DF3966A

For CIPN model, paclitaxel solution (Onatax®, 100 mg/16.7 ml; cod 018155) was kindly provided by Prof. Thiago M. Cunha (Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Brazil). For the in vivo experiments, DF3966A (Dompé farmaceutici S.p.A., L’Aquila, Italy) was dissolved in water (30 mg/10 ml), and orally given at a dose of 30 mg/kg every 12 h for 14 days during the induction phase of CIPN. On days 1, 3, 5, and 7, DF3966A was administrated 1 h after paclitaxel.
For HSR model, paclitaxel (Selleckchem, USA, cod. S1150) was intravenous administrated at 20 mg/kg (0.1 mL/Kg) dissolved in Cremophor EL (polyoxyl 35 castor oil, Sigma-Aldrich, cod. 238470) or in PEG400/TWEEN80 (Sigma-Aldrich). Vehicle DF3966A (saline) and DF3966A (30 mg/kg, os) were administrated 3 h before paclitaxel, while vehicle Avacopan (PEG-400/solutol-HS15 70:30, 5 mL/kg [29 (link)]) and Avacopan (30 mg/kg, os) were administrated 1 h before paclitaxel.